1 active not recruiting, 1 completed, 1 recruiting, 1 withdrawn. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 1, Completed 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow MB02: new trials by email Literature Review of MB02 trials Research Report on MB02
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-10-31 | 2025-06-03 | |
| Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 24 | 2025-06-23 | 2026-09-09 |
| A Pharmacokinetic Study Comparing MB02 And US And EU AvastinĀ® In Healthy Male Volunteers MB02, US licenced AvastinĀ®, EU approved AvastinĀ® - Healthy Volunteers | Phase 1 | Completed | mAbxience Research S.L. | 114 | 2017-12-07 | 2021-03-23 |
| TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study - Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 50 | 2014-05-20 | 2026-08-28 |
Colorectal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Glioblastoma (1) · Ovarian Neoplasms (1)
National Cancer Institute (NCI) (3) · mAbxience Research S.L. (1)
United States (2) · United Kingdom (1)
Kristen P Zeligs (1) · Lakshmi Nayak (1) · Muna Albayaty, MBChB,FFPM,MSc (1) · Sunu Valasseri, MBBS, MSc (1) · Susanna V Ulahannan (1)
P30CA006516 (1), U01CA062490 (1), U01CA076576 (1), U10CA180868 (1), UM1CA186689 (1), UM1CA186709 (1), UM1CA186712 (1)